Drug intelligence / Profile preview

ENTMAB-002

Development stage: Unknown
Lead developer: Entos Pharmaceuticals
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Parenteral (likely Intravenous Or Subcutaneous)

Overview

ENTMAB-002 is a monoclonal antibody developed by Entos Pharmaceuticals targeting activin and myostatin. It acts as an inhibitor of both activin and myostatin pathways, which are involved in the regulation of muscle mass and metabolic processes. The drug is being investigated primarily for the treatment of obesity and related metabolic disorders. As an antiactivin and antimyostatin antibody, it aims to promote lean mass gain while reducing fat accumulation[1][2].

Other names: ENTMAB 002ENTMAB002ENTMAB-002

Targets

GDF8 (Myostatin)ACT (Actin beta-like protein 2)

Beyond the preview

Go deeper on ENTMAB-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ENTMAB-002.

Explore the full profile